Repurchases Spark a Rally, a Metastasis Vanishes, and a Biotech Approval Dream Collapses

One company lit a fire under its shares with a repurchase plan, another stunned investors with a metastasis disappearing for nearly a year, while a biotech approval dream collapsed under the weight of a brutal second FDA rejection.

$1,000 in just seven stocks in 2004 could have turned into a million-dollar portfolio today…

Back then… one financial expert begged people to look at Nvidia -- when it was trading at just $1.10!

Now… he’s urging you to look at a new group of seven stocks…

Check this Out (The NEXT Magnificent Seven)  

Wall Street turned red on Tuesday as JPMorgan slid and dragged bank stocks lower, wiping out early gains. Even with slightly cooler inflation data, investors stayed cautious ahead of more earnings and as near-term Fed rate cuts still look unlikely.

Amgen (NASDAQ: AMGN) is making a calculated move deeper into obesity care, not by launching a new drug, but by attacking the market’s most stubborn constraint, patient access.

The company has entered into a research collaboration with Ro to study how insurance rules, prior authorization requirements, and reimbursement gaps shape real-world access to GLP-1 obesity treatments across the U.S.

This is not a symbolic partnership. It is Amgen acknowledging a reality many drugmakers prefer to ignore.

If you qualify medically but cannot get coverage, the therapy might as well not exist.

Access Becomes Strategy

Using Ro’s large-scale telehealth data, Amgen will map where patients drop out of the treatment funnel and why.

That insight feeds directly into how future obesity drugs are developed, priced, and positioned with payers.

When you think about the next generation of obesity therapies, access design now matters as much as efficacy curves.

Why This Separates Amgen From the Pack

Most competitors are racing to be first to market or best in class. Amgen is preparing for what happens after approval, when insurers, employers, and regulators decide who actually gets treated.

Obesity is becoming a systemic problem, not just a molecular problem, and Amgen is choosing to solve the system early.

This move signals long-term thinking in a market that is about to get crowded, politicized, and far more cost-sensitive.

U.S. Bancorp (NYSE: USB) just made one of its most consequential strategic moves in years, agreeing to acquire BTIG, a Wall Street brokerage and investment bank, in a deal valued at up to $1 billion in cash and stock.

This is not about headlines or deal volume. It is about repositioning.

By bringing BTIG in-house, U.S. Bancorp is expanding well beyond its traditional strengths in consumer, commercial, and payments banking and stepping decisively into capital markets where relationships, reach, and credibility matter.

Fee Engines Beat Rate Cycles

BTIG adds investment banking, institutional trading, equity research, and prime brokerage, all fee-driven businesses that behave very differently from spread-based banking.

If you have followed how banks smooth earnings through cycles, you know diversification like this reduces dependence on interest rates and makes revenue more durable.

This deal allows U.S. Bancorp to offer advice, underwriting, trading, and balance-sheet support under one roof.

You do not need to be a banker to see why that matters. When strategic conversations start earlier, the bank already in the room tends to win more wallet share.

Execution Risk Stays Contained

This is not a cold acquisition. U.S. Bancorp and BTIG have worked together for more than a decade, lowering integration risk and speeding execution.

This move signals that U.S. Bancorp is no longer content being labeled a strong regional bank. It wants to compete as a more complete financial institution, and this deal marks the start of that shift.

Warren Buffett is holding a record $325 billion in cash — not by choice, but because traditional value has vanished.

With government spending surging and inflation quietly eroding purchasing power, sitting still is no longer neutral.

That’s why attention is shifting toward a sector most investors have ignored for years.

Certain gold producers are generating real cash flow, trading at steep discounts, and benefiting from renewed domestic mining support.

One major miner stands out as exceptionally well-run, deeply undervalued, and positioned for the next phase of capital rotation.

The full breakdown — including four smaller miners — is available now.

L3Harris Technologies (NYSE: LHX) just secured one of the most consequential forms of backing a defense contractor can receive, a $1 billion U.S. government commitment to support the expansion of its rocket motor business.

The funding supports L3Harris’ plan to carve out its missile propulsion unit into a new, publicly listed company expected to debut in 2026.

That unit produces rocket motors for Patriot, THAAD, Tomahawk, and Standard Missile systems, hardware that now sits at the center of modern deterrence strategy.

Capacity Becomes National Security

Demand for missile propulsion has surged faster than global capacity can respond.

By stepping in directly, the U.S. government is prioritizing speed, reliability, and domestic control.

If you have been watching defense procurement closely, you can see the shift. Washington is no longer just buying equipment; it is shaping the industrial base behind it.

Why This Elevates L3Harris

L3Harris will retain majority control of the new entity, keeping it tightly linked to its broader defense portfolio while unlocking focused investment and execution.

You do not need to follow defense stocks daily to understand the advantage here.

Long-term volume visibility, reduced execution risk, and preferred supplier status are competitive edges that compound over years, not quarters.

And when you think about where future defense dollars flow, companies embedded this deeply into national priorities tend to stay there.

👉 Click here to get our closing report to your cell for free!

Tryhard Holdings Limited [THH] $55.05 (+138.31%)

TryHard jumped after announcing a $10M share repurchase program, signaling confidence in its valuation and future cash flow.

Briacell Therapeutics Corp [BCTX] $10.92 (+43.12%)

BriaCell surged after reporting a durable complete resolution of a lung metastasis lasting 11 months in its Bria-OTS breast cancer study.

TTM Technologies [TTMI] $93.15 (+19.59%)

TTM Technologies jumped as investors positioned ahead of its Needham Growth Conference presentation, fueling momentum in the AI-linked hardware trade.

Atara Biotherapeutics, Inc [ATRA] $4.37 (-25.68%)

Atara extended losses after the FDA issued a second Complete Response Letter for EBVALLO, unexpectedly rejecting the single-arm ALLELE study as insufficient for accelerated approval.

Passage Bio Inc [PASG] $14.27 (-20.32%)

Passage Bio slid after CEO William Chou sold stock, fueling investor concern about insider confidence following the recent run-up.

Wealthfront Corp [WLTH] $10.47 (-16.84%)

Wealthfront dipped after reporting its first post-IPO earnings as investors reacted to rising expenses and softer profitability metrics, despite revenue growth.

Liquidity is rising as the Fed shifts toward easier monetary policy.

Institutional capital continues flowing into crypto at record levels, while a pro-crypto administration accelerates favorable regulation.

Mid-term elections historically reward market-friendly policies—and after months of consolidation, conditions are aligning for a powerful move.

Nothing in crypto is ever guaranteed.

But this is one of the strongest setups seen in years—while prices remain relatively low.

Crypto Revolution reveals a disciplined system for building crypto wealth without gambling, sleepless nights, or chasing every price swing.

Get instant access to the book plus $788 in bonuses now.

© 2026 Boardwalk Flock LLC. All Rights Reserved.

2382 Camino Vida Roble, Suite I Carlsbad, CA 92011, United States

*The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies.

*Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.